Courts continue to rule in favor of Lilly’s lung cancer treatment patent, as the District Court for Appeals concludes generic producers like Dr Reddy’s to be potentially infringing.
Pfizer creates ‘new champion for global health’ through the combining of its business unit and Mylan to establish a pharmaceutical company.
US Federal court judge rules for Novartis to keep exclusivity of blockbuster MS drug until patent issues are settled.
Indivior launches generic of its own Suboxone film in the US, one day after court decision allows rivals to market generic versions.
Novartis exercises its option to license Ionis’ RNA-targeting cardiovascular drug, adding to its cardiovascular treatment portfolio, as Entresto reaches the three-year mark on its patent.
Patent litigations over Suboxone generics continue as US District Court grants restraining order against Alvogen.
The US Court of Appeals for the Federal Circuit removed the injunction against Dr. Reddy’s, which prevented the company from selling its Suboxone generic.
The clinical development services provider Phesi is looking to patent its method and system for developing clinical trial protocols – which enables faster patient enrollment and study completion, says CEO.
The European Patent Office has upheld protection relating to Gilead’s costly Hepatitis C drug Sovaldi, which Médecins du Monde claims prevents patients from receiving affordable treatment.
Pfizer, GW Pharma, Merck & Co, and Sanofi-Aventis are among the leading cannabis patent holders in Canada, says report.
Ncardia has entered into a non-exclusive licensing agreement with Evotec through which the drug discovery solutions company will gain access to Ncardia’s stem cell derived cellular disease modeling IP.
Clinerion has filed a patent for a technology that matches anonymized records with corresponding hospital medical records to identify potential clinical trial participants.
Arecor has entered a £45m ($56m) agreement to develop once daily injection of Cadila Pharmaceuticals’ basal insulin product using its reformulation technology.
DSM Sinochem Pharmaceuticals has licensed enzyme-based antibiotic production IP to Sandoz and accused Sinopharm Weiqida Pharmaceutical of patent infringement.
The Medicines Company announced last week that its Angiomax patent has been upheld – an 'important court decision' which affirms that working with CMOs won’t invalidate a company's patent.
Emerging markets in BRIC nations are gaining traction and will be a key revenue driver for multinational pharma companies – but not without risk.
After securing partnerships with AbbVie and Sanofi, Unilife has announced another exclusive agreement for a wearable injector device with Amgen.
The US Patent and Trademark Office (USPTO) has refused to review a challenge to Acorda Therapeutics’ patents from a group trying to block “abusive” IP claims.
US intellectual property (IP) rules and a string of recent court cases are reducing the types of inventions pharma companies can patent, and “calling into question entire portfolios,” says a specialist lawyer.
NEWS FROM CPHI
Makers of branded drugs are finding ways to extend their marketing authorisation by patenting not only molecules, but patient screening methods and ways of proving bioequivalence.
A lack of understanding and commentary on proceedings may be putting some pharma firms off opting into the UK’s Patent Box scheme, according to a legal expert.
Marinomed Biotechnologies is set to take on the ‘common cold’ in China with a new patent for an anti-viral polymer technology that prevents rhinovirus infection.
DSM has signed an antibody contract manufacturing deal focused in its intensified cell culture process, XD.
Patents, legal battles and R&D dominate drug delivery headlines
Legal battles, patent acquisitions and R&D dominate in-pharmatechnologist.com’s round up of developments in drug delivery this week with news from MonoSol, Acacia and a US University team working on GSK’s Relenza.
USPTO rejects MonoSol claims in delivery film patent fight with BDSI
The USPTO has rejected MonoSol RX’s claims that production methods for a cancer pain patch developed by BioDelivery Sciences (BDSI) infringe on manufacturing techniques it uses to make its own drug delivery films.
SSB and GE sign patent licensing deal for biomanufacturing techs
Sartorius Stedium Biotech (SSB) and GE Healthcare Life Sciences say new cross licensing deal will aid development of their respective biomanufacturing tech offerings.
Granted patents strengthens Marina Biotech's peptide drug delivery platform
Marina Biotech has strengthened its nucleic acid-peptide drug delivery platform after being granted the allowance for patents application of a library of novel peptides.
PhRMA and GPhA disagree on ‘first to file’ US patent law plan
The Pharmaceutical Research and Manufacturers of America (PhRMA) has welcomed proposed changes to US patent laws that would alter the basis for patent awards.
Endo's takeover of Penwest gets shareholder approval
Penwest Pharmaceuticals shareholders have voted in favour of Endo Pharmaceuticals takeover plan, paving the way for the $144m merger.
Biologics market worth $158bn by 2015, new report
Improving safety and efficacy coupled with drug industry desire for “stronger” patents will drive growth of the biologics sector over the next five years, according to new research.
Merrion’s GIPET gets US patent for bisphosphonates
Merrion Pharmaceuticals’ GIPET technology has been granted US patent protection for use with bisphosphonates.
Geron and Novocell set for stem cell tech patent battle
Geron says the USPTO appeals board granted a request to declare “interference” between a patent application owned by the firm and one issued to Novocell in March.
Bio-Path licenses siRNA targeted delivery tech
Bio-Path Holdings has signed an exclusive licence to develop a liposomal tumour targeting technology that delivers antisense and FAK siRNA and cuts toxicity.
Bangladesh a “huge opportunity” for growth; CEO
Bangladesh represents a “huge opportunity” to pharma, according to the CEO of Amreteck Pharma who believes that CMOs will be attracted by the low costs, which undercut China, and help the industry grow to $10bn (€6.9m) in 10 years.
India assesses if patent laws would violate TRIPS
A committee appointed by the Indian government has submitted a report into whether patent issues around microorganisms and NCEs are in compliance with TRIPS.
Judge warns Commission over patent changes
A UK judge has warned against the European Commission making rash changes following its report into big pharma blocking generics, arguing that it could damage development of new drugs.
US District finds for GSK in patent amendments case
GlaxoSmithKline (GSK) has scored a decisive victory in its efforts
to head off new US patent rules that would strike at the heart of
the way the drug industry goes about protecting its inventions.
New US biosimilars bill a disappointing distraction, says GPhA
The generic pharmaceutical industry has given short shrift to the
latest congressional attempt to construct a viable approval pathway
for biosimilars in the US.
GSK's disdain is blatant over new rules for patent
GlaxoSmithkline (GSK) has expressed its disdain for looming changes
to drug patent application rules in the US and has launched a
lawsuit to try and stop them coming into force next month.
Patent changes and the pharma industry
Pharmaceutical companies are being urged to develop strategies in
an effort to deal with the controversial new patent rules that come
into force in the US in November.
'No-touch' testosterone therapy proves positive
Australian drug delivery specialist Acrux has reported positive
results in Phase II trials of its innovative under-arm lotion
formulation for testosterone replacement therapy.
Industry news in brief
LabTechnologist.com brings you its periodic round up of industry
news with developments at Applied Biosystems, MFIC, Oxford Gene
Technology, PerkinElmer and Syagen.
Pall continues patent tussle with Entegris
The ongoing intellectual property tussle between Pall and Entegris
continues with Pall claiming Entegris' Impact filter cartridge line
infringes four Pall patents.
Industry news in brief
LabTechnologist.com presents its periodic round up of recent
industry news with new developments at Agilent, Beckman Coulter,
Carl Zeiss, DuPont, Luminex and PerkinElmer.
Patenting stem cells is 'ethical'
A recent article published in the journal Stem Cell has advocated
the patenting of isolated stem cell lines.
Circuit printing technology enters the market
Advances in organic electronics have allowed UK-based Novalia to
develop a proprietary technology for circuit printing on packaging
- using conventional printing equipment - which can be used to
identify when a package has been tampered...
Bayer licenses delivery tech for wound care products
Finnish company DelSitech has signed a license agreement with Bayer
Innovation, a subsidiary of the Germany's Bayer group, in a deal
that could lead to the creation of a new generation of wound care
Indian contract manufacturer matures
Indian chemicals firm Syschem has decided to move from being just a
contract manufacturer to making and selling its own its own active
pharmaceutical ingredients (APIs) & intermediates.
GE's IP expert offers tips on China
China offers Western firms a huge opportunity, but those operating
in the country should be very mindful of introducing key
Nektar opts for payout to avoid court showdown over PEGylation
Biopharmaceutical firm Nektar has agreed to fork out $25m (€20m) to
settle a patent lawsuit by the University of Alabama in Huntsville
(UAH) concerning the company's PEGylation delivery technology
currently used in eight approved...